Dissociative Symptoms in Bipolar Disorder: Impact on Clinical Course and Treatment Response

Luca Steardo Jr.†*, Elvira Anna Carbone‡, Enrica Ventura¹, Renato de Filippis††, Mario Luciano³†, Cristina Segura-Garcia‡† and Pasquale De Fazio††

¹Psychiatric Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy, ²Psychiatric Unit, Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy, ³Department of Psychiatry, University of Campania “L. Vanvitelli”, Naples, Italy

Background: Dissociative symptoms are under recognized and scarcely studied by clinicians and researchers in patients with bipolar disorder (BD). We examined the relationship between dissociative symptoms and the psychotic features in patients with BD and assessed clinical and socio-demographic characteristics more frequently associated with dissociative symptoms and treatment response.

Methods: Participants were 100 adult outpatients with BD. They were screened with semi-structured interview to collect socio-demographic and clinical characteristics; the Dissociative Experiences Scale-II (DES-II) and the ALDA scale were used to assess dissociative psychopathologies and response to treatment with mood stabilizers, respectively.

Results: DES score (mean 31.7 ± 21.7) correlated with clinical variables, BD features, and course of illness. Psychotic symptoms, mixed features, and previous suicide attempts significantly predicted DES score \(F_{(3, 47)} = 39.880, p < 0.001, R^2_{\text{corrected}} = 0.713\]. Dissociative symptoms were inversely correlated with poor response to treatment \(r = −0.593; p < 0.001\).

Limitations: Cross-sectional design with a small sample and backward clinical assessment of psychotic symptoms.

Conclusions: Dissociative phenomena are closely related to the presence of psychotic symptoms, mixed features, and previous suicide attempts in BD, especially in BD-I. Given the close association between dissociative and psychotic symptoms, this association could represent a diagnostic indicator of BD-I that may guide the clinician to plan the most appropriate treatment.

Keywords: dissociative symptoms, bipolar disorder, clinical course, treatment response, psychotic symptoms

INTRODUCTION

Dissociative symptomatology includes a variety of processes and phenomena along a continuum from adaptive coping strategies to more pathological states (1). The 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines dissociative symptoms as “a disruption of and/or discontinuity in the normal integration of consciousness, memory, identity,
emotion, perception, body representation, motor control, and behavior,” and identifies five components of dissociation: depersonalization, derealization, amnesia, identity confusion, and identity alteration (2).

Two major theories have been proposed to explain the etiology of dissociative symptoms. The “trauma theory” considers dissociation as the coping strategy adopted to deal with severe anxiety symptoms associated with traumatic experiences (3–5). On the other hand, the “disrupted sleep theory” considers the distortion of cognitions, emotions, and sensations associated with prolonged sleep deprivation as the trigger for the experience of dissociative symptoms (6, 7).

Current evidence suggests that the assessment of dissociative symptoms could be useful in differentiating patients with BD from those with unipolar major depression during depressive episodes. It has been reported that patients with BD are more likely to report dissociative symptoms than those patients with unipolar depression (8). Moreover, dissociative symptoms may precede the onset of the disorder and could be a risk factor for the development of BD (9). Besides, dissociative symptoms are frequently associated with a worse prognosis and a greater number of mood fluctuations (10–14). Further, available data suggest that the presence of dissociative symptoms is considered a marker of poor treatment response in BD (15). Despite dissociative symptoms can have a potential impact on the psychopathological burden of patients with BD, only a few studies have assessed the relationship between dissociative and psychotic symptoms and treatment response to mood stabilizers.

The aims of the present study are to assess: (1) the relationship between the presence of dissociative symptoms and psychotic symptoms in patients with BD; (2) the clinical and socio-demographic characteristics more frequently associated with dissociative symptoms; and (3) the potential role of dissociative symptoms on the response to treatment with mood stabilizers.

**METHODS**

**Participants and Procedures**

This is a naturalistic and uncontrolled cross-sectional observational study. Patients that consecutively referred to the psychiatric outpatients unit of the University Hospital Mater Domini of Catanzaro, from May 2019 to January 2020 were recruited. Trained psychiatrists evaluated every participant. Patients underwent a clinical interview by means of the Diagnostic and Statistical Manual of Mental Disorders-fifth edition (DSM-5) (16) to make the diagnosis and to ascertain if participants were eligible according to all the inclusion and exclusion criteria.

Patients were included in the study if they met the following criteria: (1) age between 18 and 65 years, (2) diagnosis of type-I (BD-I) or type-II (BD-II) bipolar disorder according to the Diagnostic and Statistical Manual of Mental Disorders-fifth edition (DSM-5) (2) clinically stabilized. Patients were deemed stabilized if item 1 (severity of the disease) of the Clinical Global Impressions for Bipolar Patients (CGI-BP) scale was ≤2 (17). No other inclusion criteria were selected to obtain a sample as similar as possible to patients routinely seen in the real world. Patients were considered ineligible in case of: clinically diagnosed dementia, diagnosis of intellectual disability from mild to severe according to DSM-5 (corresponding to IQ < 70); alcohol or substance abuse over the last twelve months; another medical condition associated with psychiatric symptoms (e.g., temporal lobe epilepsy, multiple sclerosis, brain trauma, malignant disease); or conditions that did not allow the completion of the assessment (e.g., language problems, dyslexia, or poor knowledge of the Italian language).

After receiving a full description of the study aims, all participants provided written informed consent according to the Ethical Committee’s guidelines. The study was carried out in accordance with the latest version of the Declaration of Helsinki and was approved by the local Research Ethics Committee of “Regione Calabria, sezione Area Centro” (N. 307).

A statistical power analysis was done with Gpower 3.1 for sample size estimation; with an alpha = 0.05 and a power = 0.95, the projected sample size needed with an effect size = 0.15 was minimum 89 participants.

**Assessments**

**Socio-Demographic and Clinical Characteristics**

Recruited patients underwent a semi-structured interview to collect socio-demographic and clinical characteristics using an *ad-hoc* schedule. Data on age, gender, civil status, education, occupation, family history of psychiatric illnesses, medical or psychiatric comorbidity, onset and longitudinal course of the disorder (number of depressive/hypo/manic episodes), suicidal ideation, and previous psychiatric hospitalizations and ongoing treatment were recorded.

**Dissociative Experiences Scale-II (DES-II)**

DES-II is a self-assessment measure developed by Bernstein and Putnam (18) and translated into Italian for the screening of dissociative psychopathologies. It consists of 28 items that describe dissociative experiences (amnesia, absorption, depersonalization, and derealisation). Patients are asked to indicate with a percentage the frequency they have experienced them (0% never; 100% always). The final score is given by the sum of the scores of the individual items divided by the number of total items and can therefore be included between 0 and 100: scores >30 are associated with a diagnosis of dissociative disorder.

**ALDA Scale**

The ALDA rating scale assesses response to treatment with mood stabilizers in bipolar patients (19–21). The scale comprises two sections to rate lithium response Section A Section B, and a total score. Section A evaluates the effectiveness of the ongoing treatment with a mood stabilizer, with a score ranging from 1 to 10 (1 = no response; 10 = excellent response); Section B consists of 5 items to be scored from 0 to 2 to be subtracted from criterion A. The five subdomains of criterion B consider the

Abbreviations: BD, Bipolar Disorder; BD-I, Bipolar Disorder type I; BD-II, Bipolar Disorder type II; CGI-BP, Clinical Global Impressions for Bipolar Patients; DES-II, Dissociative Experiences Scale-II; DSM-5, Diagnostic and Statistical Manual of Mental Disorders 5th edition.
number of episodes before the start of treatment, the frequency of episodes outside the treatment period, the duration of treatment, compliance with therapy, and the presence of polypharmacy. The total score on the Alda scale is divided into three sub-items: 0–3 = poor response; 4–6 = moderate response; 7–10 = good response.

### Statistical Analyses
Statistical analyses were performed with the Statistical Package for Social Sciences, version 26 (SPSS, Chicago, IL, USA).

Descriptive statistics were calculated for socio-demographic and clinical characteristics as well as for other relevant assessment instruments. Data are presented as means and standard deviations (SD) or frequencies and percentages (%), as appropriate. The association between DES and the most relevant clinical characteristics was studied through Spearman’s correlation test. Forward stepwise multiple linear regression analysis was run to ascertain the independent predictors of DES-II score among clinical variables and BD features controlling for sex and age. Finally, the association

### TABLE 1 | Socio-demographic and clinical characteristic of total sample.

|                          | DB-I |          | DB-II |          | Comparison |
|--------------------------|------|----------|-------|----------|------------|
|                          | N = 55 | Mean | SD | N = 45 | Mean | SD | Statistics | P |
| **Socio-demographic characteristics** | | | | | | | | |
| Age                      | 45.0 | 14.4 | 48.3 | 13.3 | * | t = −1.178 | 0.242 |
| Gender                   | Male | 27 | 54 | 23 | 46 | | | | |
| Education                | 13.3 | 3.6 | 13.8 | 3.0 | | | t = −0.684 | 0.495 |
| Having partner*          | Yes | 45 | 82 | 39 | 87 | | | x² = 0.433 | 0.511 |
| Employed*                | Yes | 30 | 55 | 30 | 67 | | | x² = 1.515 | 0.218 |
| Family history of psychiatric disorders* | Yes | 39 | 57 | 29 | 43 | | | x² = 0.475 | 0.491 |
| **Clinical variables** | | | | | | | | |
| Age at onset              | 24.5 | 5.4 | 30.7 | 12.7 | * | t = −3.307 | 0.001 |
| Age first psychiatric contact | 27.6 | 6.3 | 32.9 | 12.8 | | | t = −2.730 | 0.008 |
| Age first depressive episode | 29.2 | 11.0 | 25.2 | 8.9 | | | t = 1.942 | 0.055 |
| Age first manic episode  | 28.6 | 6.9 | 27.6 | 7.4 | | | t = 0.504 | 0.617 |
| Age first hypomaniac episode | 33.4 | 10.9 | 29.3 | 8.4 | | | t = 1.895 | 0.062 |
| Tot number of depressive episodes | 7.5 | 5.9 | 2.9 | 1.4 | * | t = 4.961 | <0.001 |
| Tot number of manic episodes | 3.8 | 2.9 | 0 | 0 | | | | | |
| Tot number of hypomaniac episodes | 3.8 | 3.9 | 2.6 | 1.1 | * | t = 2.002 | <0.05 |
| Tot number of episodes | 3.8 | 3.9 | 5.4 | 2.2 | | | t = 5.319 | <0.001 |
| Tot number episodes last year | 0.8 | 0.8 | 0.8 | 0.7 | | | t = −0.092 | 0.927 |
| Suicide attempts*        | Yes | 28 | 88 | 4 | 13 | | | x² = 20.083 | <0.001 |
| Aggressive behaviors*    | Yes | 41 | 72 | 16 | 28 | | | x² = 15.351 | <0.001 |
| Psychotic symptoms*      | Yes | 43 | 78 | 0 | 0 | | | | | |
| Seasonality*             | Yes | 21 | 41 | 25 | 57 | | | x² = 2.314 | 0.128 |
| Tot number of hospitalizations | 0.7 | 0.9 | 0.6 | 0.9 | | | t = 0.533 | 0.596 |
| Illness duration         | 20.5 | 14.2 | 17.6 | 11.1 | | | t = 1.138 | 0.258 |
| Course of illness*       | Irregular | 16 | 29 | 16 | 36 | | | x² = 0.475 | 0.491 |
| BD features              | | | | | | | | |
| Anxious features*        | Yes | 44 | 70 | 19 | 30 | | | x² = 15.153 | <0.001 |
| Mixed features*          | Yes | 37 | 77 | 11 | 23 | | | x² = 19.090 | <0.001 |
| Antidepressants switch*  | Yes | 24 | 83 | 5 | 17 | | | x² = 12.716 | <0.001 |
| Current treatment        | | | | | | | | |
| Antipsychotics*          | Yes | 47 | 85 | 36 | 80 | | | x² = 0.522 | 0.47 |
| Antidepressants*         | Yes | 8 | 15 | 5 | 11 | | | x² = 0.258 | 0.611 |
| Lithium*                 | Yes | 32 | 58 | 27 | 60 | | | x² = 0.034 | 0.854 |
| Mood stabilizers*        | Yes | 31 | 57 | 27 | 60 | | | x² = 0.134 | 0.714 |
| Combined therapy*        | Yes | 47 | 85 | 39 | 87 | | | x² = 0.000 | 0.862 |
| ALDA                     | | | | | | | | |
| Total score              | 3.6 | 2.0 | 4.8 | 2.0 | | | t = −3.022 | 0.003 |
| Response*                | Poor | 29 | 52 | 11 | 24 | | | x² = 10.286 | 0.006 |
| Moderate                 | Moderate | 23 | 42 | 25 | 56 | | | | | |
| Good                     | 3 | 6 | 9 | 20 | | | | | |
| DES-II                   | | | | | | | | |
| Total score              | 43.0 | 19.4 | 18.0 | 15.6 | | | t = 6.963 | <0.001 |

*Data are presented as frequencies and percentages (%). Significant results are in bold.

BD-I, type I bipolar disorder; BD-II, type II bipolar disorder; DES II, Dissociative Experience Scale II.
between DES and Alda scores was studied with Pearson’s correlation analysis.

The level of statistical significance was set at \( p < 0.05 \).

**RESULTS**

The total sample consisted of 100 patients (55 BD-I and 45 BD-II), 50% males, mean age 46.5 ± 13.9 years. Table 1 illustrates the socio-demographic and clinical characteristics of participants according to their diagnosis. Almost half of patients were in a stable relationship, employed and had a positive history for psychiatric disorders. The mean age at onset was 27.30 ± 9.85 and the duration of illness was 19 ± 12.99 years. Significant differences emerged in clinical variables, BD features and ALDA score according to diagnosis. Only patients with BD-I reported psychotic symptoms (43/55); patients reported psychotic symptoms during manic (51%), depressive (9%), or both episodes (40%).

Table 2 includes the results of Spearman’s correlations between DES-II and the clinical features of patients. Significant correlations emerge for all variables except age at onset of bipolar disorder. Successively a linear regression analysis was performed to determine the relationship between clinical variables and DES. Successively a linear regression analysis was performed to determine the relationship between clinical variables and DES. The results indicated that there was a significant effect of clinical variables on DES \( (F_{(3, 47)} = 39.880, p < 0.001, R^2 \text{ corrected} = 0.713) \). The individual predictors were examined further and indicated that mixed features \( (t = 3.762, p < 0.001) \), psychotic symptoms \( (t = 4.932, p < 0.001) \) and previous suicide attempt \( (t = 3.928, p < 0.001) \) were significant predictors in the model (Table 3).

Finally, a significant negative association between DES and ALDA scores \( (t = −0.593; p < 0.001) \) emerged from the correlation analysis.

**DISCUSSION**

The main finding of our study is the presence of a stable correlation between dissociative symptoms psychotic symptom, mixed features, and previous suicides attempts in BD. Our study is the first to demonstrate that the occurrence of dissociative dimension is higher in BD type I, especially in those with psychotic features and in those who present a greater clinical severity (22–24). In our sample, 45% of patients developed psychotic symptoms, all of them with BD-I. Moreover, such correlation is related to clinical severity as shown by the higher DES-II total score in patients with a higher number of episodes, aggressive behaviors, seasonality, mixed features, and poor response to mood stabilizers (25). Possibly, as previously demonstrated for other mental disorders, dissociative symptoms are more expressed in patients with psychotic symptoms (26). According to Allen et al. (27), who developed the theory of “dissociative detachment,” dissociative phenomena “undermines the individual’s grounding in the outer world,” rendering the individual susceptible to developing psychotic features. Additionally, other authors have highlighted the inverse relationship in which dissociation is a defense against the disorganization and acute distress generated by psychosis (28). Other possible mechanisms might be the early trauma exposure that predisposes to a higher psychopathological load among different psychiatric disorders, including BD (29, 30). However, we did not assess the impact of trauma in this study and therefore this explanation remains speculative.

In addition, mixed characteristics were associated with a higher DES-II total score. Mixed features are associated with a lack of response to mood stabilizers in BD and this could explain why patients with dissociative are refractory to treatment (31). Mixed features are often triggered by antidepressant therapy, and this feature appeared associated with greater dissociative symptomatology as demonstrated in our study.

Patients with a lifetime history of suicide attempts reported higher rates of dissociative symptoms and a higher DES-II total score. Suicide could represent an attempt to cope with dissociative symptoms or a last attempt to reach a dissociative state (32, 33). Thus, the link between dissociative symptoms and suicidal behaviors represent an interesting topic in order

**TABLE 2 |** Spearman’s correlations between DES-II and clinical features.

| Variable                  | DES score  |
|---------------------------|------------|
| Total number of episodes  | 0.533**    |
| Antidepressants’ switch   | 0.497**    |
| Suicide attempts          | 0.551**    |
| Psychotic features        | 0.759**    |
| Aggressive behavior       | 0.339**    |
| Mixed features            | 0.674**    |
| Anxious features          | 0.603**    |
| Course of illness (regular) | −0.417**  |
| Seasonality               | 0.386**    |
| Age at onset              | −0.063     |

**p < 0.01. Significant results are in bold.

**TABLE 3 |** Multiple linear regression model.

| Dependent variable | Independent variable | B     | Standard error | Beta  | t         | P    | 95% Confidence interval |
|--------------------|----------------------|-------|----------------|-------|-----------|------|------------------------|
|                    |                      |       |                |       |           |      | Lower                  | Higher     |
| DES-II             | Mixed features       | 13.964| 3.711          | 0.359 | 3.762     | <.001| 6.484                  | 21.443     |
|                    | Psychotic features   | 16.23 | 3.291          | 0.444 | 4.932     | <.001| 9.598                  | 22.862     |
|                    | Previous suicide attempt | 11.673| 2.972          | 0.33  | 3.928     | <.001| 5.684                  | 17.663     |
to improve the risk assessment and to develop models of intervention in patients with BD.

The significant correlation between DES and poor response to treatment with mood stabilizers emerged. We can explain it because clinical variables associated with dissociative symptoms are superimposable with those that predispose to refractoriness to drug treatment. In fact, this correlation gains further support from the significant correlations between clinical variables and dissociative symptoms that emerged from our study (i.e., the higher number of lifetime episodes, the seasonality, the antidepressant switch, the aggressive behavior, the anxious features, and the irregular course of illness) that are all predictive factors of poor response to treatment for patients with BD. So of poor response to treatment in patients with bipolar disorder (3-4).

The authors acknowledge some limits, the first being the cross-sectional design with a small sample size that narrows conclusions about the reverse causality. Surely, a longitudinal evaluation of dissociative symptoms would allow clarifying their association with clinical variables. Another limit is the backward clinical assessment of psychotic symptoms. The recall bias of incompleteness and imprecision of the patients’ memories represents another limitation. Ultimately, patients completed the protocol while clinically stabilized so, assessing dissociative symptoms during the acute phase of the BD, although interesting was not possible. For all these reasons, the authors have planned follow-up assessments and including patients in the acute depressive, manic, or hypomanic episodes to counterbalance these limits.

CONCLUSIONS

Dissociative phenomena are closely related to the presence of psychotic symptoms, mixed features, and previous suicide attempts in BD, especially in BD-I. Given the close association between dissociative and psychotic symptoms, this association could represent a diagnostic indicator of BD-I. Therefore, we consider it extremely important to evaluate the presence of ongoing dissociation in BD to guide the clinician to plan the most appropriate treatment. Future studies should investigate in greater depth the causes underlying this association and the most appropriate therapeutic strategies to reduce the impact that these symptoms have on the course of BD.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Regione Calabria, sezione Area Centro. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

LS: conceptualization. LS and ML: methodology. LS, ML, and CS-G: formal analysis. LS, EAC, and RF: investigation. EV and RD: data curation. LS, EAC, and ML: writing the original draft preparation. CS-G and PD: writing and review and editing. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors are grateful to patients who took part in this study.

REFERENCES

1. Holmes EA, Brown RJ, Mansell W, Fearon RP, Hunter ECM, Frasquillo F, et al. Are there two qualitatively distinct forms of dissociation? A review and some clinical implications. Clin Psychol Rev. (2005) 25:1–23. doi: 10.1016/j.cpr.2004.08.006

2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-5. 5th ed. Arlington, VA: American Psychiatric Publishing (2013), doi: 10.1176/appi.books.9780890425596

3. Lee WE, Kwok CHT, Hunter ECM, Richards M, David AS. Prevalence and childhood antecedents of depersonalization syndrome in a UK birth cohort. Soc Psychiatry Psychiatr Epidemiol. (2012) 47:253–61. doi: 10.1007/s00127-012-0327-7

4. Stein DJ, Koenen KC, Friedman MJ, Hill E, McLaughlin KA, Petukhova M, et al. Dissociation in posttraumatic stress disorder: evidence from the world mental health surveys. Biol Psychiatry. (2013) 73:302–12. doi: 10.1016/j.biopsych.2012.08.022

5. Sar V. Parallel-distinct structures of internal world and external reality: disavowing and re-claiming the self-identity in the aftermath of trauma-generated dissociation. Front Psychol. (2017) 8:216. doi: 10.3389/fpsyg.2017.00216

6. van der Kloot D, Merckelbach H, Giesbrecht T, Lynn SJ. Fragmented sleep, fragmented mind: the role of sleep in dissociative symptoms. Perspect Psychol Sci. (2012) 7:59–75. doi: 10.1177/1745691612437597

7. Van Heugten-Van Der Kloot D, Giesbrecht T, Merckelbach H. Sleep loss increases dissociation and affects memory for emotional stimuli. J Behav Ther Exp Psychiatry. (2015) 47:9–17. doi: 10.1016/j.jbtep.2014.11.002

8. Chatterjee SS, Pal A, Mallik N, Ghosal M, Saha G. Dissociative experience in unipolar and bipolar depression: exploring the great divide. Clin Psychopharmacol Neurosci. (2018) 16:262–6. doi: 10.9758/cpn.2018.16.3.262

9. Hariri AG, Gulec MY, Oren gul FFC, Sumbul EA, Elbay RY, Gulec H. Dissociation in bipolar disorder: relationships between clinical variables and childhood trauma. J Affect Disord. (2015) 184:104–10. doi: 10.1016/j.jad.2015.05.023

10. Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Cearns M, et al. Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Mol Psychiatry. (2020) 26:2457–70. doi: 10.1038/s41380-020-0889-5

11. Mula M, Fini S, Preve M, Masini M, Giovannini I, Cassano GB. Clinical correlates of depersonalization symptoms in patients with bipolar disorder. J Affect Disord. (2009) 115:252–6. doi: 10.1016/j.jad.2008.08.001

12. Yayla S, Bakim B, Tankaya O, Ozer OA, Karamustafalioglu O, Ertek in H, et al. Psychiatric comorbidity in patients with conversion disorder and prevalence of dissociative symptoms. J Trauma Dissec. (2015) 16:29–38. doi: 10.1080/15299732.2014.938214

13. Depp CA, Dev S, Eyler LT. Bipolar depression and cognitive impairment: shared mechanisms and new treatment avenues. Psychiatr Clin North Am. (2016) 39:95–109. doi: 10.1016/j.psc.2015.09.004
The relationship between childhood trauma and psychotic symptoms: a transdiagnostic two-step cluster analysis. J Affect Disord. (2019) 259:104–11 doi: 10.1016/j.jad.2019.08.049

Wang L, Yin Y, Bian Q, Zhou Y, Huang J, Zhang P, et al. Immature defense mechanisms mediate the relationship between childhood trauma and onset of bipolar disorder. J Affect Disord. (2021) 278:672–7. doi: 10.1016/j.jad.2020.10.029

Swann AC. Mixed features: evolution of the concept, past and current definitions, and future prospects. CNS Spectr. (2017) 22:161–9. doi: 10.1017/S1092852916000882

Calati R, Bensassi I, Courtet P. The link between dissociation and both suicide attempts and non-suicidal self-injury: meta-analyses. Psychiatry Res. (2017) 251:103–14. doi: 10.1016/j.psychres.2017.01.035

Connors R. Self-injury in trauma survivors: 1. functions and meanings. Am J Orthopsychiatry. (1996) 66:197–206. doi: 10.1037/h0080171

López-Villarreal A, Sánchez-Morla EM, Jiménez-López E, Martínez-Vizcaíno V, Aparicio AI, Mateo-Sotos I, et al. Predictive factors of functional outcome in patients with bipolar I disorder: a five-year follow-up. J Affect Disord. (2020) 272:249–58. doi: 10.1016/j.jad.2020.03.140

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Steardo, Carbone, Ventura, de Filippis, Luciano, Segura-Garcia and De Fazio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.